Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alvotech
< Previous
1
2
3
Next >
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 19, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
January 10, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
November 28, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
November 21, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
November 14, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
November 10, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
November 07, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
October 12, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 03, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
September 25, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
September 20, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Changes to the Leadership Team
September 05, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 30, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
August 29, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
August 22, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Completes $100 Million Convertible Bond Private Placement
July 31, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 28, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
JNJ
TEVA
Alvotech to Participate in Jefferies Healthcare Conference
May 31, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
May 24, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
May 19, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
May 17, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Issues Annual Equality Report Covering 2022
May 15, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
May 10, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
May 04, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
May 03, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.